I don't understand either. I looked at the quarterly, compared...

I don't understand either. I looked at the quarterly, compared to the half yearly and just could not see a reason for the sp fall. Enormous potential to grow sales in the US, costs should reduce post the integration of mediate
cannot help but wonder what was behind the run to 40+ followed by large on market pre arranged trades. Is the opposite happening now?
Fundementals look ok, looking to next update to confirm growth in sales and trimming costs.
Does anyone have a view on the sp fall? Can't be solely related to bio selloff?